Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Health Management and Economics Research Center, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Cardiovasc Drugs Ther. 2021 Aug;35(4):829-839. doi: 10.1007/s10557-020-07130-6. Epub 2021 Feb 9.
Abdominal aortic aneurysm (AAA) is a life-threatening condition which, in the absence of increasing diameter or rupture, often remains asymptomatic, and a diameter greater than 5.5 cm requires elective surgical repair. This study aimed to evaluate the cost-effectiveness of endovascular repair (EVAR) versus open surgical repair (OSR) in patients with AAA through a systematic review of published health economics studies.
Using a systematic review method, an electronic search was conducted for cost-effectiveness studies published on AAA (both in English and Persian) on PubMed, Embase, ISI/Web of Science (WoS), SCOPUS, Global Health databases, and the national databases of Iran from 1990 to 2020 including the keywords "cost-effectiveness", "endovascular", "open surgical", and "abdominal aortic aneurysms". The quality of the studies was assessed using the Quality of Health Economic Studies (QHES) checklist.
In total, 958 studies were found, of which 16 were eligible for further study. All studies were conducted in developed countries, and quality-adjusted life years (QALY) and life years (LY) were used to measure the outcomes. According to the QHES checklist, most studies were of good quality. In European countries and Canada, EVAR has not been cost-effective, while most studies in the United States regard this technique as a cost-effective intervention. For example, incremental cost-effectiveness ratio (ICER) values ranged from $14,252.12 to $34,446.37 per QALY in the USA, while ICER was €116,600.40 per QALY in Portugal.
According to the results, the EVAR technique has been more cost-effective than OSR for high-risk patients, but the need for continuous follow-up, increased costs, and re-intervention over the long term and for low-risk patients has reduced the cost-effectiveness of this method. As the health systems vary among different countries (i.e. quality of care, cost of devices, etc.), and due to the heterogeneity of studies in terms of the follow-up period, time horizon, and threshold, all of which are inherent features of economic evaluation, generalizing the results should be done with much caution, and policymaking must be based on national evidence.
腹主动脉瘤(AAA)是一种危及生命的疾病,如果直径不增加或不破裂,通常没有症状,直径大于 5.5 厘米则需要择期手术修复。本研究旨在通过系统评价已发表的健康经济学研究,评估腹主动脉瘤患者血管内修复(EVAR)与开放手术修复(OSR)的成本效益。
使用系统评价方法,对 1990 年至 2020 年在 PubMed、Embase、ISI/Web of Science(WoS)、SCOPUS、全球健康数据库和伊朗国家数据库中以英文和波斯文发表的 AAA 成本效益研究进行电子检索,使用的关键词为“cost-effectiveness”、“endovascular”、“open surgical”和“abdominal aortic aneurysms”。使用健康经济研究质量评估清单(QHES)评估研究质量。
共发现 958 项研究,其中 16 项符合进一步研究标准。所有研究均在发达国家进行,使用质量调整生命年(QALY)和生命年(LY)来衡量结果。根据 QHES 清单,大多数研究质量较高。在欧洲国家和加拿大,EVAR 并不具有成本效益,而美国的大多数研究认为该技术具有成本效益。例如,在美国,增量成本效益比(ICER)值范围为每 QALY 14,252.12 美元至 34,446.37 美元,而葡萄牙为每 QALY 116,600.40 欧元。
根据结果,EVAR 技术在高危患者中比 OSR 更具成本效益,但需要长期持续随访、增加成本和再次干预,以及在低危患者中,降低了该方法的成本效益。由于不同国家的卫生系统(即护理质量、设备成本等)不同,并且由于研究在随访期、时间范围和阈值方面存在异质性,所有这些都是经济评估的固有特征,因此,在推广结果时应格外谨慎,决策必须基于国家证据。